Cellectar Biosciences, Inc. (FWB:NV40) Financings
Financings
| Raise | Date |
|---|---|
| Warrant exercise of common stock upon exercise of existing warrants Announced: about US$5.8M · US$5.25 a share · Warrants at US$6 for 60 months · Ladenburg Thalmann & Co. Inc. Dealers: Ladenburg Thalmann & Co. Inc. (lead) Use of proceeds: Working capital and general corporate purposes, Phase 1b study of CLR 125 in triple-negative breast cancer, and preparing a Conditional Marketing Authorization filing with the EMA | Oct 7, 2025 |
| Public offering of class A Units and Class B Units Closed: US$6.9M raised · US$5 a unit · Warrants at US$5.25 for 60 months · Ladenburg Thalmann & Co. Inc. Dealers: Ladenburg Thalmann & Co. Inc. (lead) Insiders: The offering includes participation from executive management Use of proceeds: General corporate purposes, working capital and operating expenses, and a Phase 1b study of CLR 125 in triple-negative breast cancer | Jul 2, 2025 |
| Warrant exercise of common stock upon exercise of existing warrants Announced: about US$2.5M · US$0.3041 a share · Ladenburg Thalmann & Co. Inc. Dealers: Ladenburg Thalmann & Co. Inc. (lead) Use of proceeds: General corporate purposes, including working capital and operating expenses | Jun 5, 2025 |